Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00044616 · ClinicalTrials.gov registry record · Phase 4
Relapse Prevention for Bipolar Type-II Disorder
A Phase 4 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 4
- Development phase
- 180
- Enrollment target
NCT00044616: Completed Phase 4 study, sponsored by University of Pennsylvania.
NCT00044616 is a Phase 4 study that has completed, run by University of Pennsylvania. The registered enrollment target is 180 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00044616, a Phase 4 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 180 participants
- Enrollment target
Study Summary
This 62-week study will compare the safety and effectiveness of fluoxetine (Prozac®), lithium, the combination of these two medications, and placebo in treating and preventing recurrent depressive episodes in people with bipolar type II disorder.
Interventions
- DRUG Lithium
- DRUG Fluoxetine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2001-02 |
| Est. Completion | 2007-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00044616
The ClinicalTrials.gov registry entry for NCT00044616 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lithium is the first listed.
NCT00044616 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00044616 about?
NCT00044616 is a clinical study titled "Relapse Prevention for Bipolar Type-II Disorder". This 62-week study will compare the safety and effectiveness of fluoxetine (Prozac®), lithium, the combination of these two medications, and placebo in treating and preventing recurrent depressive episodes in people with bipolar type II disorder.
What is the current status of trial NCT00044616?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 180 participants. The study started on 2001-02. Estimated completion is 2007-01.
What interventions are being tested in trial NCT00044616?
The interventions under investigation include: Lithium (DRUG), Fluoxetine (DRUG).
Who is sponsoring clinical trial NCT00044616?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.